A descriptive study of Relapsing-Remitting Multiple Sclerosis (RRMS) treated with first disease modifying therapies (DMTs) in current UK clinical practice: patterns of clinical decision making and the patient experience of relapse

ISRCTN ISRCTN66678006
DOI https://doi.org/10.1186/ISRCTN66678006
Secondary identifying numbers CFTY720DGB02
Submission date
24/04/2012
Registration date
26/07/2012
Last edited
29/03/2018
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
This is a research study being carried out at six hospitals in the UK. It will look back over 3 years at how well patients with multiple sclerosis (MS) respond to medicines known as disease modifying therapies (DMTs), which are used to treat MS. We are also looking at the effect a relapse has on the everyday life of a person with MS. DMTs have all been tested in clinical trials and approved for treating patients, but in this study we want to get more information about the experience of patients using them. This study is designed to increase understanding of how well DMTs work as initial treatments for Relapsing Remitting MS (RRMS), in patients’ real-world setting rather than in formal clinical trials.
We understand the progression and accumulation of disability in the later stages of MS quite well, but the physical, psychological and financial impact of relapses in early disease is less clear and potentially underestimated. Differing perceptions between physicians and patients on the nature and severity of a relapse may contribute to this.

Who can participate?
Patients with a diagnosis of RRMS, and who started a DMT for the first time in 2008, will be eligible to participate.

What does the study involve?
Patients will be identified at 6 UK centres and will be invited to participate by post. They will be sent an information sheet, and details of a person to contact if they require further information. Once the consent has been returned (by post), the participant will be enrolled in the study and will receive another package by post. Included in this pack are a retrospective questionnaire to provide information on the participant’s experience of their last relapse, and three short questionnaires to inform us of their current health status. Once this is returned, the participant will have completed their role in study.
We will also look at the medical records of those who allow us to do so. We will look at the number of relapses that occur in the 3 years after the first prescription of DMTs, any changes in medication, and the number of clinic visits needed during this time.

What are the possible benefits and risks of participating?
There are no direct risks or benefits to the participant in this study as there will be no change in patient care. The benefit is adding to the literature in this area to inform clinical and policy decisions about patient care.

Where is the study run from?
This study is coordinated independently by pH Associates. The six centres taking part will be: The Royal Victoria Infirmary - Newcastle, Queens Hospital - Romford, Charing Cross Hospital - London, Leicester General Infirmary - Leicester, Norfolk and Norwich University Hospital – Norwich, and Morristen Hospital - Swansea.

When is study starting and how long is it expected to run for?
May 2012 to December 2012.

Who is funding the study?
Novartis Pharmaceuticals UK Ltd (UK)

Who is the main contact?
Heather Davies
heather.davies@novartis.com

Lucinda Davies (pH Associates)
lucinda@phassociates.com

Contact information

Dr Heather Davies
Scientific

Novartis Pharmaceuticals UK Ltd
200 Frimley Business Park
Frimley
GU16 7SR
United Kingdom

Study information

Study designMulti-centre observational study
Primary study designObservational
Secondary study designOther
Study setting(s)GP practice
Study typeScreening
Scientific titleA multi-centre observational study of relapsing-remitting multiple sclerosis (RRMS) treated with first disease modifying therapies (DMTs) in current UK clinical practice: patterns of clinical decision making and the patient experience of relapse
Study objectivesTo describe the number of documented relapses experienced by people with MS (PwMS) in the first 3 years following DMT initiation
Ethics approval(s)Yes - London-Bromley, approved 4th April 2012, ref: 12 LO 0248
Health condition(s) or problem(s) studiedMultiple Sclerosis
Intervention1. Retrospective questionnaire on the patient’s experience of the last relapse
2. Three short health questionnaires
3. Review of medical records over 3 years from the first prescription of a disease-modifying treatment for relapsing-remitting multiple sclerosis
Intervention typeOther
Primary outcome measureTo describe the number of documented relapses experienced by patients with MS in the first 3 years following DMT initiation
Secondary outcome measures1. To describe the number of documented relapses experienced by patients with MS in the 3 years following DMT initiation by severity
2. To describe the DMT prescribing patterns in the first three years following DMT initiation
3. To compare clinician-documented and patient-reported relapse symptoms
4. To describe the change in patient contact with health care professionals resulting from relapse
5. To describe the financial impact of a relapse on patients with MS
6. To describe the impact of a relapse on patients’ attitudes to DMT
Overall study start date01/06/2012
Completion date01/12/2012

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants150
Key inclusion criteria1. Patients with RRMS by 2005 MacDonald criteria
2. Patients initiated on DMT for the first time after 1 January 2008 and at least 36 months before date of screening for inclusion
3. Patients who consent to complete the questionnaire and for their medical records to be reviewed for the purposes of healthcare research
4. Patients who are able to complete the study questionnaires or have a carer who is able and willing to record the patient’s responses to the study questionnaires
Key exclusion criteria1. Patients who are unwilling or unable to provide patient consent
2. Patients who are unable to complete the study questionnaires themselves and have no appropriate carer able and willing to assist them
Date of first enrolment01/06/2012
Date of final enrolment01/12/2012

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Novartis Pharmaceuticals UK Ltd
Frimley
GU16 7SR
United Kingdom

Sponsor information

Novartis Pharmaceuticals Ltd (UK)
Industry

c/o Dr Heather Davies
200 Frimley Business Park
Frimley
GU16 7SR
United Kingdom

Phone +44 1276 694402
Email heather.davies@novartis.com
ROR logo "ROR" https://ror.org/039s6n838

Funders

Funder type

Industry

Novartis Pharmaceuticals UK Ltd (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

29/03/2018: No publications found, verifying study status with prinicipal investigator.
10/02/2016: No publications found, verifying study status with principal investigator.